DNTH Latest News, Press Relases and Analysis

All

Press Releases

12 days ago - By: Zacks Investment Research - Mentions: LXRX

Dianthus Therapeutics, Inc. (DNTH) Reports Q3 Loss, Lags Revenue Estimates

12 days ago - By: Dianthus Therapeutics, Inc.

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results

12 days ago - By: Dianthus Therapeutics, Inc.

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results

13 days ago - By: Zacks Investment Research - Mentions: DAWN

Day One Biopharmaceuticals, Inc. (DAWN) Reports Q3 Loss, Tops Revenue Estimates

13 days ago - By: Dianthus Therapeutics, Inc.

Dianthus Therapeutics to Participate in Four Investor Conferences During November

2 months ago - By: Benzinga

Analyst Expectations For Dianthus Therapeutics's Future

18 days ago - By: Zacks Investment Research - Mentions: CYTK

Dianthus Therapeutics, Inc. (DNTH) Expected to Beat Earnings Estimates: Should You Buy?

19 days ago - By: Dianthus Therapeutics, Inc.

Dianthus Therapeutics Highlights New Claseprubart Data Presented During 2025 AANEM Annual Meeting

19 days ago - By: Dianthus Therapeutics, Inc.

Dianthus Therapeutics Highlights New Claseprubart Data Presented During 2025 AANEM Annual Meeting

a month ago - By: Dianthus Therapeutics, Inc.

Dianthus Therapeutics Announces Exclusive License Agreement with Leads Biolabs for DNTH212, a First and Potentially Best-In-Class, Phase 1 Ready Bifunctional BDCA2 & BAFF/APRIL Inhibitor for Severe Autoimmune Diseases

a month ago - By: Dianthus Therapeutics, Inc.

Dianthus Therapeutics Announces Exclusive License Agreement with Leads Biolabs for DNTH212, a First and Potentially Best-In-Class, Phase 1 Ready Bifunctional BDCA2 & BAFF/APRIL Inhibitor for Severe Autoimmune Diseases

2 months ago - By: Dianthus Therapeutics, Inc.

Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2025 AANEM Annual Meeting

2 months ago - By: Dianthus Therapeutics, Inc.

Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2025 AANEM Annual Meeting

2 months ago - By: Benzinga - Mentions: APP ADBE AI GM ...

General Motors To Rally More Than 24%? Here Are 10 Top Analyst Forecasts For Friday

3 months ago - By: The Motley Fool

Dianthus (DNTH) Q2 Loss Widens 80%

2 months ago - By: Dianthus Therapeutics, Inc.

Dianthus Therapeutics, Inc. Announces Closing of its Upsized $288 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

2 months ago - By: Dianthus Therapeutics, Inc.

Dianthus Therapeutics, Inc. Announces Closing of its Upsized $288 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

2 months ago - By: Dianthus Therapeutics, Inc.

Dianthus Therapeutics, Inc. Announces Pricing of Upsized $251 Million Underwritten Public Offering

2 months ago - By: Dianthus Therapeutics, Inc.

Dianthus Therapeutics, Inc. Announces Pricing of Upsized $251 Million Underwritten Public Offering

2 months ago - By: Dianthus Therapeutics, Inc.

Dianthus Therapeutics, Inc. Announces Proposed $150 Million Underwritten Public Offering

2 months ago - By: Dianthus Therapeutics, Inc.

Dianthus Therapeutics, Inc. Announces Proposed $150 Million Underwritten Public Offering

2 months ago - By: Investor's Business Daily - Mentions: ARGX AZN SNY

Why Dianthus Therapeutics, Up 47% In Four Weeks, Just Surged Again

2 months ago - By: Dianthus Therapeutics, Inc.

Dianthus Therapeutics Announces Positive Data for Claseprubart (DNTH103) from the Phase 2 MaGic Trial in Generalized Myasthenia Gravis, Supporting Its Potential Best-In-Class Profile

2 months ago - By: Dianthus Therapeutics, Inc.

Dianthus Therapeutics to Host Conference Call and Webcast to Discuss Results from Phase 2 MaGic Trial of Claseprubart (DNTH103) in Generalized Myasthenia Gravis

2 months ago - By: Dianthus Therapeutics, Inc.

Dianthus Therapeutics to Host Conference Call and Webcast to Discuss Results from Phase 2 MaGic Trial of Claseprubart (DNTH103) in Generalized Myasthenia Gravis

3 months ago - By: Toi Management, LLC - Mentions: TOI

The Oncology Institute Announces Changes to Board of Directors

3 months ago - By: Zacks Investment Research - Mentions: CVAC

Dianthus Therapeutics, Inc. (DNTH) Reports Q2 Loss, Lags Revenue Estimates

3 months ago - By: Dianthus Therapeutics, Inc.

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results

3 months ago - By: Dianthus Therapeutics, Inc.

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results

3 months ago - By: Zacks Investment Research - Mentions: INO

Earnings Preview: Dianthus Therapeutics, Inc. (DNTH) Q2 Earnings Expected to Decline

3 months ago - By: Zacks Investment Research - Mentions: SEER

DIANTHUS THERAPEUTICS INC (DNTH) Stock News

DNTH Latest News, Press Relases and Analysis

Dianthus Therapeutics, Inc. (DNTH) Reports Q3 Loss, Lags Revenue Estimates

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results

Day One Biopharmaceuticals, Inc. (DAWN) Reports Q3 Loss, Tops Revenue Estimates

Dianthus Therapeutics to Participate in Four Investor Conferences During November

Analyst Expectations For Dianthus Therapeutics's Future

Dianthus Therapeutics, Inc. (DNTH) Expected to Beat Earnings Estimates: Should You Buy?

Dianthus Therapeutics Highlights New Claseprubart Data Presented During 2025 AANEM Annual Meeting

Dianthus Therapeutics Highlights New Claseprubart Data Presented During 2025 AANEM Annual Meeting

Dianthus Therapeutics Announces Exclusive License Agreement with Leads Biolabs for DNTH212, a First and Potentially Best-In-Class, Phase 1 Ready Bifunctional BDCA2 & BAFF/APRIL Inhibitor for Severe Autoimmune Diseases

Dianthus Therapeutics Announces Exclusive License Agreement with Leads Biolabs for DNTH212, a First and Potentially Best-In-Class, Phase 1 Ready Bifunctional BDCA2 & BAFF/APRIL Inhibitor for Severe Autoimmune Diseases

Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2025 AANEM Annual Meeting

Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2025 AANEM Annual Meeting

General Motors To Rally More Than 24%? Here Are 10 Top Analyst Forecasts For Friday

Dianthus (DNTH) Q2 Loss Widens 80%

Dianthus Therapeutics, Inc. Announces Closing of its Upsized $288 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Dianthus Therapeutics, Inc. Announces Closing of its Upsized $288 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Dianthus Therapeutics, Inc. Announces Pricing of Upsized $251 Million Underwritten Public Offering

Dianthus Therapeutics, Inc. Announces Pricing of Upsized $251 Million Underwritten Public Offering

Dianthus Therapeutics, Inc. Announces Proposed $150 Million Underwritten Public Offering

Dianthus Therapeutics, Inc. Announces Proposed $150 Million Underwritten Public Offering

Why Dianthus Therapeutics, Up 47% In Four Weeks, Just Surged Again

Dianthus Therapeutics Announces Positive Data for Claseprubart (DNTH103) from the Phase 2 MaGic Trial in Generalized Myasthenia Gravis, Supporting Its Potential Best-In-Class Profile

Dianthus Therapeutics to Host Conference Call and Webcast to Discuss Results from Phase 2 MaGic Trial of Claseprubart (DNTH103) in Generalized Myasthenia Gravis

Dianthus Therapeutics to Host Conference Call and Webcast to Discuss Results from Phase 2 MaGic Trial of Claseprubart (DNTH103) in Generalized Myasthenia Gravis

The Oncology Institute Announces Changes to Board of Directors

Dianthus Therapeutics, Inc. (DNTH) Reports Q2 Loss, Lags Revenue Estimates

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results

Earnings Preview: Dianthus Therapeutics, Inc. (DNTH) Q2 Earnings Expected to Decline

Seer, Inc. (SEER) Reports Q2 Loss, Beats Revenue Estimates